US20200360625A1 - Drug delivery device - Google Patents
Drug delivery device Download PDFInfo
- Publication number
- US20200360625A1 US20200360625A1 US16/543,051 US201916543051A US2020360625A1 US 20200360625 A1 US20200360625 A1 US 20200360625A1 US 201916543051 A US201916543051 A US 201916543051A US 2020360625 A1 US2020360625 A1 US 2020360625A1
- Authority
- US
- United States
- Prior art keywords
- reservoir
- mold half
- fluid
- reservoir chamber
- plastics material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims description 54
- 229940079593 drug Drugs 0.000 claims description 52
- 239000012530 fluid Substances 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 23
- 239000004033 plastic Substances 0.000 claims description 20
- 229920003023 plastic Polymers 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 16
- 238000004891 communication Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 5
- 229920001169 thermoplastic Polymers 0.000 claims description 2
- 239000004416 thermosoftening plastic Substances 0.000 claims description 2
- 238000009966 trimming Methods 0.000 claims 2
- 238000012384 transportation and delivery Methods 0.000 abstract description 18
- 239000013543 active substance Substances 0.000 abstract description 10
- 210000003491 skin Anatomy 0.000 description 45
- 210000004207 dermis Anatomy 0.000 description 21
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- -1 interleukin-2 Chemical compound 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000012815 thermoplastic material Substances 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 229940032024 DPT vaccine Drugs 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3287—Accessories for bringing the needle into the body; Automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
- A61M5/282—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by compression of deformable ampoule or carpule wall
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/285—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened
- A61M5/286—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened upon internal pressure increase, e.g. pierced or burst
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/285—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened
- A61M5/288—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened by piercing without internal pressure increase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3143—Damping means for syringe components executing relative movements, e.g. retarders or attenuators slowing down or timing syringe mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3245—Constructional features thereof, e.g. to improve manipulation or functioning
- A61M2005/3247—Means to impede repositioning of protection sleeve from needle covering to needle uncovering position
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6081—Colour codes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M5/2422—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
- A61M5/2425—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by compression of deformable ampoule or carpule wall
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
Definitions
- the present invention relates to drug delivery devices and methods of delivering a drug intradermally.
- the present invention relates to intradermal delivery of a liquid drug.
- the skin comprises two layers, the outer or upper surface called the epidermis, and the internal surface referred to as the dermis.
- the epidermis does not contain any blood vessels and it is dependent on the underlying dermis for nutrient delivery and waste disposal via diffusion.
- the inner layer, the dermis is composed of two layers, the more superficial papillary dermis and the deeper reticular dermis.
- the papillary dermis is thinner and consists primarily of loose connective tissue containing small capillaries, elastic fibers, reticular fibers and some collagen.
- the deeper reticular dermis consists of a thicker connective tissue containing larger blood vessels, interlaced elastic fibers and core spindles of collagen fibers arranged in layers parallel to the surface.
- the reticular layer also contains many antigen-presenting cells, fibroblasts, mast cells, nerve endings, and lymphatics. Because of the high amount of blood vessels, lymphatics and antigen presenting cells in the dermis, this is an ideal site for delivery of drugs and/or antigens.
- the outer layer, the epidermis has a thickness of about 0.05 to 2 mm and the dermis has a thickness between about 1.5 and 4 mm.
- the needle must penetrate the skin to a depth of no more than 5 mm, preferably between about 2 and 4 mm. It is very difficult to control an injection to this shallow depth.
- a fine gauge needle is inserted at a 45° angle to try and get the agent into the dermis.
- United States Patent Application No. 2005/0124967 is directed to a method for directly delivering a high molecular weight substance into an intradermal space within mammalian skin comprising administering the substance through at least one hollow needle having an outlet with an exposed height between 0 and 1 mm, said outlet being inserted into the skin to a depth of between 0.3 mm and 2 mm, such that delivery of the substance occurs at a depth between 0.3 mm and 2 mm and a microneedle for intradermal injection of a high molecular weight pharmaceutical substance, wherein the microneedle has a length and outlet selected for its suitability for specifically delivering the substance into the dermis.
- U.S. Pat. No. 5,527,288 discloses an intradermal drug delivery device for delivering a liquid drug to a subject via the subject's skin, comprising a housing having a lower surface for application to the skin of the subject; means for affixing the housing in position with the lower surface in contact with the subject's skin; and a drug reservoir within the housing.
- the reservoir is in the form of an expansible-contractible chamber which is expanded when filled with the drug and which can be contracted to dispense the drug therefrom.
- a single hollow needle is associated with the drug reservoir and extends through the lower surface, having an inner end communicating with the drug reservoir and an outer end projecting outwards a sufficient distance so as to penetrate through the epidermis and into the dermis when the housing is pressed against the skin.
- the device also includes means for actively discharging the drug from the reservoir to the subject's skin via the needle.
- U.S. Pat. No. 6,689,118 is directed to a method of making an intradermal injection into the skin of an animal to obtain systemic delivery or to induce an immune response.
- the method comprises providing a drug delivery device including a needle cannula having a forward needle tip and a needle cannula being in fluid communication with a substance contained in said drug delivery device; inserting the needle tip into the skin of an animal and engaging the surface of the skin with a skin engaging surface of a limiter portion such that the skin engaging surface of the limiter portion limits penetration of the needle tip into the dermis layer of the skin of the animal; and expelling the substance from the drug deliver device through the needle tip into the skin of the animal to expose the injected substance to the microcirculatory blood vasculature and the lymphatic plexuses.
- U.S. Pat. No. 6,569,143 is directed to another related method of making an intradermal injection comprising providing a drug delivery device; inserting a needle tip into the skin of an animal whereby penetration of the needle tip is limited to the dermis layer of the skin of the animal; and expelling the substance from said drug delivery device through the needle tip into the skin of the animal.
- U.S. Pat. No. 5,997,501 describes an intradermal drug delivery device for the delivery of at least one drug to a subject via the subject's skin.
- the device comprises a housing having a lower surface; a drug reservoir located with the housing; a cover that is adjustable engaged with the housing from a first extended position to a second retracted position such that the cover is proximal to the lower surface of the housing when the cover is retracted and the cover is distal to the lower surface of the housing when the cover is extended; means for affixing the cover in position with the lower surface of the housing in contact with the subject's skin; a single hollow needle fixed to the cover and having a first end in communication with the drug reservoir and a second end projecting outwards no further than the lower surface of the housing when the cover is extended, and to penetrate through the epidermis and into the dermis when the cover is retracted; and means for actively discharging the drug from the reservoir to the subject's skin via the needle.
- the device of the present invention is based on a unique technology that allows a liquid pharmaceutical formulation to be delivered into the skin of the patients through a fine needle without the significant pain experienced by regular injection needles.
- the drug is injected into the layers of the skin, avoiding the pinching of the nerves. This reduces pain significantly or eliminates it totally in many cases thus improving the acceptance and compliance to treat many diseases like diabetes.
- the present invention addresses the problems of the prior art by providing a novel type of reservoir for a drug and a delivery device for delivering the drug from the reservoir to a specific depth of skin.
- a method of preparing the drug reservoir and a method of delivering a fluid drug are also provided.
- a reservoir for carrying an active agent comprises a fillable bladder having flexible walls that can be sealed.
- a method of manufacturing such a reservoir comprises the steps of: opposing two layers of thermoplastic film; heating the film; applying a vacuum mold to the outer surface of each layer of film to form a bubble; and allowing the film to cool.
- the method comprises preparing a sheet of thermoplastic material having a series of wells or depressions as fillable reservoirs. A top sheet is then applied to seal the reservoirs.
- a method of filling the reservoir comprises filling the bladder with a fluid drug; and sealing the reservoir.
- a device for delivery of a fluid drug to an animal comprising a housing having an upper end and a lower end, the lower end having an aperture therein and the upper end being adapted to receive a drive actuator.
- a reservoir chamber is disposed within the housing and operatively linked to the drive actuator.
- the reservoir chamber has a base and wall(s). The wall may be a continuous circular wall or a connected set of walls.
- Within the reservoir chamber there is a flexible reservoir filled with the fluid drug.
- a microneedle is mounted on the base so as to transverse the base of the chamber such that the top of the needle is in communication with the chamber and the tip of the needle extends in the housing below the chamber.
- the reservoir chamber is located at a predetermined distance from the lower end of the housing whereby abutment of the base of the chamber to the lower end of the housing acts as a stop to provide a predetermined length of travel of the needle through the aperture when the drive mechanism or actuator is activated.
- the length of travel is optimally set to deliver the drug intradermally.
- the device also preferably includes biasing means to maintain the reservoir chamber in the upper position within the housing, in the absence of pressure on the actuator thus retaining the needle tip inside the housing.
- the device in another embodiment, includes a lower housing and an upper housing that fits over the lower housing.
- the upper housing is continuous with the actuator that causes the reservoir to descend and contact the needle end.
- a method of administering a fluid drug through the skin of an animal comprises providing a device as defined above; applying the lower surface of the device to the skin; exerting pressure on the drive mechanism thereby lowering the reservoir chamber and causing the needle tip to travel through the aperture and into the skin a predetermined distance; and applying continued pressure on the actuator to cause the upper end of the needle to pierce the reservoir and continuing to apply pressure so that all the contents of the reservoir flow through the needle into the skin.
- FIGS. 1A to 1G illustrate the steps in the manufacture of a drug reservoir according to the present invention
- FIGS. 2A to 2J Illustrate the operation of one embodiment of a delivery device of the invention
- FIGS. 3A and 3B illustrate another embodiment of a delivery device
- FIGS. 4A to 4C illustrate yet another embodiment of a delivery device.
- a novel type of drug reservoir comprises a fillable bladder.
- the reservoir is formed between two layers of plastic film.
- the two layers can be formed from two sheets or from one sheet folded in half. When two sheets are used, the sheets may comprise the same material, thickness, etc. or they may be two different types of sheets.
- the present invention provides for a drug delivery device incorporating a disposable reservoir.
- the device may be provided as a single-use, disposable device or a multi-use device.
- the device comprises a housing that has an upper end and a lower end.
- the term “upper” is used to refer to the surface furthest away from an individual skin and the term “lower” is used to refer to the part of the device that contacts a patient's skin.
- An actuator is mounted at the top of the housing.
- the actuator is used to activate a drive mechanism.
- One example of a drive mechanism is a plunger that travels up and down within the housing.
- a reservoir chamber is slideably mounted within the housing.
- the reservoir chamber holds a reservoir filled with a liquid.
- the reservoir chamber is operatively linked to the drive mechanism.
- the reservoir chamber has a micro needle mounted on the lower surface of the chamber.
- FIGS. 1A-G A process for the manufacture of one embodiment of the reservoir is shown in FIGS. 1A-G .
- a sheet of thermoplastic material 10 is folded in half to provide a first surface 12 and a second surface 14 .
- the sheet 10 is folded so that the first surface and the second surface overlap each other. Then the sheet is heated to soften the film.
- FIG. 1C illustrates a mold 18 applied to each of the surfaces 12 , 14 .
- the mold for each side may be of similar or different shapes.
- a vacuum is applied to the mold halves, a bubble 20 is formed and at the same time the boundary 22 of the reservoir shape is sealed.
- a vertical path 24 is left open for filling of the reservoir. As shown in FIG.
- FIG. 1D the mold halves 18 are removed and the sheet 10 including the bubbles 20 are cooled to room temperature.
- the filling process is demonstrated in FIG. 1E .
- the film is preferably oriented with the vertical path 24 open at the top for filling to avoid the formation of air pockets during the filling process.
- a fine dispensing nozzle 26 is inserted into the vertical path 24 and a controlled amount of drug 27 is inserted into the reservoir.
- the open end 30 of the vertical path 24 is then heat sealed as shown in FIG. 1F .
- the bubble shaped reservoir 20 can then be trimmed as shown in FIG. 1G from the remaining sheets of plastic film or the bubble shapes can be partially trimmed and the bubbles can be stored in a roll format.
- the reservoir is formed by preparing a sheet of material having a series of wells or depressions. The wells are filled with a drug and then an upper sheet is applied to cover and seal the open end of the wells.
- the reservoir comprises a fillable, sealable bladder of thermoplastic material.
- a round, blue bubble may indicate that the reservoir contains insulin and a square pink bubble may indicate a DPT vaccine.
- the reservoir of the present invention can be used to store many different kinds of active agents. Color coding can be used to identify the agent and/or dose strength.
- the present invention also provides a device and method for delivery of the drug stored in the reservoir to an animal, preferably a human.
- the device comprises an outer housing.
- the outer housing can be made of any durable material, preferably a hard plastic.
- the outer housing can take various shapes, e.g. it can be round, oval, hexagonal, square etc.
- the outer housing can incorporate various colours to identify the agent and/or dose strength.
- the outer housing defines an internal chamber that includes an open top at the upper end and a base having an aperture at the lower end.
- a reservoir chamber is fitted inside the housing.
- the reservoir chamber is adapted to receive a disposable reservoir such as that described above.
- a microneedle is mounted in the bottom platform of the reservoir chamber with its upper (non-skin contacting) end protruding upward and just below the reservoir and the skin-contacting tip extending beyond the bottom of the chamber.
- the reservoir chamber frictionally engages the internal wall(s) of the housing.
- a drug reservoir or bubble is contained within the reservoir chamber.
- a drive actuator is operatively linked to the reservoir chamber.
- the drive actuator may include a flexible dome or an upper casing.
- the reservoir chamber typically comprises an open upper end, an internal chamber to hold the reservoir and a base platform with the needle mounted so that it transects the base.
- a retraction mechanism such as a vacuum bulb or a spring is also optionally included.
- the delivery device is placed on the skin with the lower end of the housing touching the skin.
- the drive mechanism is then actuated to drive the reservoir chamber downwards until the base platform of the reservoir chamber hits the base of the housing. This causes the needle to exit through the aperture in the base of the housing a predetermined distance and enter into the skin to a predetermined depth. Further downward pressure on the plunger compresses the drug filled reservoir and causes it to be pierced by the upper end of the needle.
- retraction means cause the needle to be retracted back into the housing for disposal.
- the device 50 comprises housing 52 .
- the housing has an open upper end 54 and a bottom base 56 defining an interior chamber 58 that optionally includes a spring.
- the bottom base comprises an aperture 60 .
- the interior of the housing is adapted to receive a reservoir chamber 62 having a chamber ledge 62 A circumferentially disposed around the interior of the upper end of the chamber 62 .
- the reservoir chamber comprises a base 64 and a surrounding wall 66 extending upwards from the base defining a chamber 62 with an open top 68 .
- a filled reservoir body 70 is located in the reservoir chamber.
- a single hollow needle 72 is associated with the reservoir chamber 62 .
- the needle 72 extends through the base 64 of the chamber 62 and has a cannula with an upper end 74 communicating with the interior 75 of the reservoir chamber and a lower end 78 projecting out of the chamber and down a predetermined distance.
- the open top 68 of the reservoir chamber is adapted to receive an actuator 80 .
- the actuator comprises a plunger 82 having an activation flange 84 at one end and a stopper 86 at the other end. In the initial position of the device as provided and as shown in FIGS.
- the base 64 of the reservoir chamber 62 is held at a predetermined distance from the interior surface 88 of the base 56 of the housing by at least one releasable latch 90 which retains the chamber in position by the interaction of the latch 90 with a latch retainer 92 .
- the latch 90 includes a notch 91 .
- an upper housing 96 encases the plunger 80 .
- the distance the needle travels can be varied depending on the desired application and on the bubble position and the length of the needle.
- the device can be adapted to have the needle travel a distance between about 0.5 mm to about 10 mm.
- the device of the invention can be adapted for intradermal, subcutaneous or intramuscular injections.
- the needle preferably travels from about 3 mm to 8 mm.
- the needle gauge is preferably 25 to 84 gauge although different gauge needles can be used.
- FIGS. 2A to 2J illustrate the operation of the device in the initial state as described above.
- FIGS. 2C and 2D illustrate the device in the initial state as described above.
- the base 56 of the housing 52 is placed against the skin.
- the latch 90 is released from the retainer 92 .
- the actuator 80 is connected to the reservoir chamber 62 via a notch 100 and tab 102 connector and the reservoir chamber will be forced down until the base 64 of the reservoir chamber 62 hits the interior surface 88 of the housing base 56 and the chamber is stopped from any further downward movement.
- the distance that the needle extends is about 0.5 to 10 mm, preferably 0.5 to 5 mm, more preferably from about 3 mm to about 5 mm, even more preferably from about 1.5 to 3 mm.
- the outer layer of skin, the epidermis typically has a thickness of about 0.5 to 2 mm.
- the inner layer, the dermis has a thickness of about 1.5 to 3 mm.
- the dermis comprises two layers, the papillary layer and the reticular layer.
- the reticular layer contains many blood vessels and lymph vessels, making it a desirable area for delivery of active agents. Below the dermis is the subcutaneous layer and then muscle.
- the distance that the tip of the needle can extend beyond the lower outer surface of the housing is selected to be optimum for insertion in the dermis or subcutaneous layer.
- the lower tip of the needle 78 exits the aperture 60 .
- the downward travel of the reservoir chamber 62 is limited when the base 64 of the chamber contacts the base 56 of the housing. In this way the travel of the needle through the aperture 60 is also limited so as to limit the depth of penetration of the needle into the skin.
- the components of the device have been configured so that the distance that the bottom of the chamber travels is translated into a predetermined travel for the needle through the aperture in the bottom of the housing to provide a certain skin penetration.
- the tab 102 is released from the notch 100 and the plunger 82 descends within the reservoir chamber forcing the filled reservoir 70 downwards until it contacts the base 64 of the reservoir chamber 62 .
- the actuator 80 exerts pressure on the reservoir 70 , the reservoir 70 contacts the upper end 74 of the needle 72 and is punctured.
- the cannula of the needle 72 is now in fluid communication with the contents of the reservoir.
- the needle is preferably retracted back into the housing 52 as illustrated in FIGS. 2I and 2J .
- the position of the reservoir chamber 62 carrying the needle 72 is preferably biased to the pre-activation position by biasing means such as a spring, a vacuum bulb or a moldable bulb.
- biasing means such as a spring, a vacuum bulb or a moldable bulb.
- the base 64 of the reservoir chamber moves up in the housing thus automatically retracting the used needle into the housing. This provides for safe disposal of the device.
- the needle is preferably locked in the retracted position.
- FIG. 2J shows a retracted reservoir chamber that is locked in position when tab 102 slides into indent 104 .
- an actuator 106 is continuous with an upper casing 108 that fits over a housing 110 .
- the housing 110 receives a reservoir chamber 112 that has a needle 114 transversely mounted through its base 116 .
- a drug reservoir 118 is contained within the chamber 112 .
- pressure on the actuator 106 causes the reservoir chamber 112 to descend until it abuts the base 120 of the housing 110 .
- the chamber 112 descends, it drives the tip 122 of the needle 114 through an aperture 124 in the housing 110 . Further pressure causes the rear 126 of the needle to puncture the reservoir 118 .
- the contents of the reservoir are expelled through the needle.
- a flexible dome fits over the plunger rod and activation flange. It is also clearly apparent the manual activation flange can be exposed.
- the device also optionally includes a spring that is located around or below the reservoir chamber base such that when pressure on the activation flange is released the compressive energy of the spring causes the needle to be retracted back into the housing.
- FIGS. 4A to 4C illustrate another embodiment of the device.
- the device 130 includes a housing 132 and an upper casing 134 .
- An actuator 136 is operably linked to a reservoir chamber 138 disposed within the housing 132 .
- a drug filled reservoir 140 is placed in the reservoir chamber 138 .
- a needle 142 is mounted so as to transverse the base 144 of the chamber 138 .
- the device also includes a spring 146 that biases the reservoir chamber 138 upwards in the housing 132 .
- the actuator 136 compresses and the reservoir chamber travels downward carrying the needle and the needle tip 148 exits the housing 132 .
- the actuator 136 compresses the drug filled reservoir 140 until the back 150 of the needle punctures the reservoir and the contents flow through the needle as shown in FIG. 4C .
- a method for delivering an effective amount of a liquid active agent to an animal preferably a human.
- the method comprises providing a drug delivery device according to the present invention, said device containing a reservoir filled with the desired drug; applying the bottom surface of the drug delivery device of the invention to the skin of an animal, applying pressure on the actuator to cause the needle to enter the skin, applying continued pressure to puncture the reservoir and deliver the contents of the reservoir through the cannula of the needle.
- the device of the present invention can be used to deliver a variety of active agents.
- drug is used loosely herein to refer to prophylactic as well as therapeutic agents.
- vaccines may be delivered using the device.
- active agents such as nucleic acids, small molecules, therapeutic proteins, hormones, analgesics, etc. in additional to traditional pharmacologic agents.
- Typical drugs include peptides, proteins or hormones such as insulin, calcitonin, calcitonin gene regulating protein, atrial natriuretic protein, colony stimulating factor, betaseton, erythropoietin (EPO), interferons such as ⁇ , ⁇ , or ⁇ interferon, somatropin, somatotropin, somatostatin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone (LHRH), tissue plasminogen activator (TPA), growth hormone release hormone (GHRH), oxytocin, estradiol, growth hormones, leuprolide acetate, factor VIII, interleukins such as interleukin-2, and analogues thereof; analgesics such as fentanyl, sufentanil, butorphanol, buprenorphine, levorphanol, morphine, hydromorphone, hydrocodone, oxymorephone, methadone, lidoca
- fluid refers to any fluid containing an active agent or communication of agents that can pass through the cannula of the microneedle. This includes a liquid, a solution, a gel, a dispersion or a fine suspension.
Abstract
Description
- The present application is a Continuation of U.S. patent application Ser. No. 11/355,000, filed Feb. 16, 2006, entitled “DRUG DELIVERY DEVICE” and assigned U.S. Patent Application Number US-2007/0191780-A1 the entire contents of which is incorporated herein by reference.
- The present invention relates to drug delivery devices and methods of delivering a drug intradermally. In particular, the present invention relates to intradermal delivery of a liquid drug.
- There has long been a desire to deliver drugs intradermally. The skin comprises two layers, the outer or upper surface called the epidermis, and the internal surface referred to as the dermis. The epidermis does not contain any blood vessels and it is dependent on the underlying dermis for nutrient delivery and waste disposal via diffusion. The inner layer, the dermis, is composed of two layers, the more superficial papillary dermis and the deeper reticular dermis. The papillary dermis is thinner and consists primarily of loose connective tissue containing small capillaries, elastic fibers, reticular fibers and some collagen. The deeper reticular dermis consists of a thicker connective tissue containing larger blood vessels, interlaced elastic fibers and core spindles of collagen fibers arranged in layers parallel to the surface. The reticular layer also contains many antigen-presenting cells, fibroblasts, mast cells, nerve endings, and lymphatics. Because of the high amount of blood vessels, lymphatics and antigen presenting cells in the dermis, this is an ideal site for delivery of drugs and/or antigens.
- A major problem, however, with intradermal delivery is the difficulty in precisely delivering the drug into the dermal layer. Generally, the outer layer, the epidermis, has a thickness of about 0.05 to 2 mm and the dermis has a thickness between about 1.5 and 4 mm. Thus, to deliver an agent to the dermis, the needle must penetrate the skin to a depth of no more than 5 mm, preferably between about 2 and 4 mm. It is very difficult to control an injection to this shallow depth. For certain types of injection, such as the Mantoux test for tuberculosis, a fine gauge needle is inserted at a 45° angle to try and get the agent into the dermis.
- Several efforts have been made to try and find reliable ways of delivering agents to the dermis. For example, United States Patent Application No. 2005/0124967 is directed to a method for directly delivering a high molecular weight substance into an intradermal space within mammalian skin comprising administering the substance through at least one hollow needle having an outlet with an exposed height between 0 and 1 mm, said outlet being inserted into the skin to a depth of between 0.3 mm and 2 mm, such that delivery of the substance occurs at a depth between 0.3 mm and 2 mm and a microneedle for intradermal injection of a high molecular weight pharmaceutical substance, wherein the microneedle has a length and outlet selected for its suitability for specifically delivering the substance into the dermis.
- U.S. Pat. No. 5,527,288 discloses an intradermal drug delivery device for delivering a liquid drug to a subject via the subject's skin, comprising a housing having a lower surface for application to the skin of the subject; means for affixing the housing in position with the lower surface in contact with the subject's skin; and a drug reservoir within the housing. The reservoir is in the form of an expansible-contractible chamber which is expanded when filled with the drug and which can be contracted to dispense the drug therefrom. A single hollow needle is associated with the drug reservoir and extends through the lower surface, having an inner end communicating with the drug reservoir and an outer end projecting outwards a sufficient distance so as to penetrate through the epidermis and into the dermis when the housing is pressed against the skin. The device also includes means for actively discharging the drug from the reservoir to the subject's skin via the needle.
- U.S. Pat. No. 6,689,118 is directed to a method of making an intradermal injection into the skin of an animal to obtain systemic delivery or to induce an immune response. The method comprises providing a drug delivery device including a needle cannula having a forward needle tip and a needle cannula being in fluid communication with a substance contained in said drug delivery device; inserting the needle tip into the skin of an animal and engaging the surface of the skin with a skin engaging surface of a limiter portion such that the skin engaging surface of the limiter portion limits penetration of the needle tip into the dermis layer of the skin of the animal; and expelling the substance from the drug deliver device through the needle tip into the skin of the animal to expose the injected substance to the microcirculatory blood vasculature and the lymphatic plexuses.
- U.S. Pat. No. 6,569,143 is directed to another related method of making an intradermal injection comprising providing a drug delivery device; inserting a needle tip into the skin of an animal whereby penetration of the needle tip is limited to the dermis layer of the skin of the animal; and expelling the substance from said drug delivery device through the needle tip into the skin of the animal.
- U.S. Pat. No. 5,997,501 describes an intradermal drug delivery device for the delivery of at least one drug to a subject via the subject's skin. The device comprises a housing having a lower surface; a drug reservoir located with the housing; a cover that is adjustable engaged with the housing from a first extended position to a second retracted position such that the cover is proximal to the lower surface of the housing when the cover is retracted and the cover is distal to the lower surface of the housing when the cover is extended; means for affixing the cover in position with the lower surface of the housing in contact with the subject's skin; a single hollow needle fixed to the cover and having a first end in communication with the drug reservoir and a second end projecting outwards no further than the lower surface of the housing when the cover is extended, and to penetrate through the epidermis and into the dermis when the cover is retracted; and means for actively discharging the drug from the reservoir to the subject's skin via the needle.
- Although multiple efforts have been made to try and provide a device for intradermal delivery, many of the prior art devices are expensive to manufacture or can only be used for one drug. In spite of all the efforts made to provide a method and/or device for intradermal delivery, there remained a need for a reliable, single-use, disposable device for intradermal delivery.
- Many people consider an injection (at best) unpleasant and (at worst) a painful encounter, no matter how well the nurse or doctor administers the shot. This is because most shots are given subcutaneously or intramuscularly, reaching deep enough into the skin to hit nerves. Part of the skin's job is to sense danger in the environment through nerve cells, and it is richly endowed with these cells—a single square inch of skin contains approximately 1,300 nerve endings. Since most injections are given subcutaneously or intramuscularly, thereby delivering drugs to be absorbed into the blood vessels, the needle generally strikes nerves and causes pain along the way. The device of the present invention is based on a unique technology that allows a liquid pharmaceutical formulation to be delivered into the skin of the patients through a fine needle without the significant pain experienced by regular injection needles. The drug is injected into the layers of the skin, avoiding the pinching of the nerves. This reduces pain significantly or eliminates it totally in many cases thus improving the acceptance and compliance to treat many diseases like diabetes.
- The present invention addresses the problems of the prior art by providing a novel type of reservoir for a drug and a delivery device for delivering the drug from the reservoir to a specific depth of skin. A method of preparing the drug reservoir and a method of delivering a fluid drug are also provided.
- In one aspect of the invention a reservoir for carrying an active agent is provided. The reservoir comprises a fillable bladder having flexible walls that can be sealed.
- A method of manufacturing such a reservoir is also provided. In one embodiment, the method comprises the steps of: opposing two layers of thermoplastic film; heating the film; applying a vacuum mold to the outer surface of each layer of film to form a bubble; and allowing the film to cool.
- In another embodiment, the method comprises preparing a sheet of thermoplastic material having a series of wells or depressions as fillable reservoirs. A top sheet is then applied to seal the reservoirs.
- A method of filling the reservoir is also provided and comprises filling the bladder with a fluid drug; and sealing the reservoir.
- In another aspect of the invention, a device for delivery of a fluid drug to an animal is provided. The term “animal” is used herein to include both human and non-human animals. The devices and methods of the invention are applicable for both human and veterinary use. The device comprises a housing having an upper end and a lower end, the lower end having an aperture therein and the upper end being adapted to receive a drive actuator. A reservoir chamber is disposed within the housing and operatively linked to the drive actuator. The reservoir chamber has a base and wall(s). The wall may be a continuous circular wall or a connected set of walls. Within the reservoir chamber, there is a flexible reservoir filled with the fluid drug. A microneedle is mounted on the base so as to transverse the base of the chamber such that the top of the needle is in communication with the chamber and the tip of the needle extends in the housing below the chamber.
- In a preferred embodiment, the reservoir chamber is located at a predetermined distance from the lower end of the housing whereby abutment of the base of the chamber to the lower end of the housing acts as a stop to provide a predetermined length of travel of the needle through the aperture when the drive mechanism or actuator is activated. The length of travel is optimally set to deliver the drug intradermally. The device also preferably includes biasing means to maintain the reservoir chamber in the upper position within the housing, in the absence of pressure on the actuator thus retaining the needle tip inside the housing.
- In another embodiment of the invention, the device includes a lower housing and an upper housing that fits over the lower housing. In this embodiment, the upper housing is continuous with the actuator that causes the reservoir to descend and contact the needle end.
- In yet another aspect of the invention, a method of administering a fluid drug through the skin of an animal is provided. The method comprises providing a device as defined above; applying the lower surface of the device to the skin; exerting pressure on the drive mechanism thereby lowering the reservoir chamber and causing the needle tip to travel through the aperture and into the skin a predetermined distance; and applying continued pressure on the actuator to cause the upper end of the needle to pierce the reservoir and continuing to apply pressure so that all the contents of the reservoir flow through the needle into the skin.
- This summary of the invention does not necessarily describe all features of the invention.
- These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:
-
FIGS. 1A to 1G illustrate the steps in the manufacture of a drug reservoir according to the present invention; -
FIGS. 2A to 2J Illustrate the operation of one embodiment of a delivery device of the invention; -
FIGS. 3A and 3B illustrate another embodiment of a delivery device; and; -
FIGS. 4A to 4C illustrate yet another embodiment of a delivery device. - The following description is of preferred embodiments.
- In one aspect of the present invention a novel type of drug reservoir is provided. The drug reservoir comprises a fillable bladder. The reservoir is formed between two layers of plastic film. The two layers can be formed from two sheets or from one sheet folded in half. When two sheets are used, the sheets may comprise the same material, thickness, etc. or they may be two different types of sheets.
- The present invention provides for a drug delivery device incorporating a disposable reservoir. The device may be provided as a single-use, disposable device or a multi-use device. The device comprises a housing that has an upper end and a lower end. As used herein, the term “upper” is used to refer to the surface furthest away from an individual skin and the term “lower” is used to refer to the part of the device that contacts a patient's skin. An actuator is mounted at the top of the housing. The actuator is used to activate a drive mechanism. One example of a drive mechanism is a plunger that travels up and down within the housing. A reservoir chamber is slideably mounted within the housing. The reservoir chamber holds a reservoir filled with a liquid. The reservoir chamber is operatively linked to the drive mechanism. The reservoir chamber has a micro needle mounted on the lower surface of the chamber. When the plunger is depressed, the reservoir housing travels downward within the housing until it stops when the bottom of the reservoir housing hits the bottom of the outer housing.
- A process for the manufacture of one embodiment of the reservoir is shown in
FIGS. 1A-G . InFIG. 1A , a sheet ofthermoplastic material 10 is folded in half to provide afirst surface 12 and asecond surface 14. Referring toFIG. 1B , thesheet 10 is folded so that the first surface and the second surface overlap each other. Then the sheet is heated to soften the film.FIG. 1C illustrates amold 18 applied to each of thesurfaces bubble 20 is formed and at the same time theboundary 22 of the reservoir shape is sealed. Avertical path 24 is left open for filling of the reservoir. As shown inFIG. 1D , the mold halves 18 are removed and thesheet 10 including thebubbles 20 are cooled to room temperature. The filling process is demonstrated inFIG. 1E . The film is preferably oriented with thevertical path 24 open at the top for filling to avoid the formation of air pockets during the filling process. Afine dispensing nozzle 26 is inserted into thevertical path 24 and a controlled amount of drug 27 is inserted into the reservoir. The open end 30 of thevertical path 24 is then heat sealed as shown inFIG. 1F . The bubble shapedreservoir 20 can then be trimmed as shown inFIG. 1G from the remaining sheets of plastic film or the bubble shapes can be partially trimmed and the bubbles can be stored in a roll format. - In another embodiment, the reservoir is formed by preparing a sheet of material having a series of wells or depressions. The wells are filled with a drug and then an upper sheet is applied to cover and seal the open end of the wells. In both embodiments the reservoir comprises a fillable, sealable bladder of thermoplastic material.
- Various colors and shapes of reservoirs can be used for different drugs. For example, a round, blue bubble may indicate that the reservoir contains insulin and a square pink bubble may indicate a DPT vaccine. The reservoir of the present invention can be used to store many different kinds of active agents. Color coding can be used to identify the agent and/or dose strength.
- The present invention also provides a device and method for delivery of the drug stored in the reservoir to an animal, preferably a human. The device comprises an outer housing. The outer housing can be made of any durable material, preferably a hard plastic. The outer housing can take various shapes, e.g. it can be round, oval, hexagonal, square etc. The outer housing can incorporate various colours to identify the agent and/or dose strength. The outer housing defines an internal chamber that includes an open top at the upper end and a base having an aperture at the lower end. A reservoir chamber is fitted inside the housing. The reservoir chamber is adapted to receive a disposable reservoir such as that described above. A microneedle is mounted in the bottom platform of the reservoir chamber with its upper (non-skin contacting) end protruding upward and just below the reservoir and the skin-contacting tip extending beyond the bottom of the chamber. The reservoir chamber frictionally engages the internal wall(s) of the housing. A drug reservoir or bubble is contained within the reservoir chamber. A drive actuator is operatively linked to the reservoir chamber. The drive actuator may include a flexible dome or an upper casing. The reservoir chamber typically comprises an open upper end, an internal chamber to hold the reservoir and a base platform with the needle mounted so that it transects the base. A retraction mechanism such as a vacuum bulb or a spring is also optionally included.
- In use, the delivery device is placed on the skin with the lower end of the housing touching the skin. The drive mechanism is then actuated to drive the reservoir chamber downwards until the base platform of the reservoir chamber hits the base of the housing. This causes the needle to exit through the aperture in the base of the housing a predetermined distance and enter into the skin to a predetermined depth. Further downward pressure on the plunger compresses the drug filled reservoir and causes it to be pierced by the upper end of the needle. This puts the cannula of the needle in fluid communication with the contents of the reservoir and as the downward pressure continues until the tip of the plunger bottoms on the base platform of the reservoir chamber, the contents of the reservoir are passed through the cannula of the needle to the skin of an animal or human subject. When the pressure on the drive mechanism is released, retraction means cause the needle to be retracted back into the housing for disposal.
- One preferred embodiment of the device and its operation is shown in
FIGS. 2A-J . Thedevice 50 compriseshousing 52. The housing has an openupper end 54 and abottom base 56 defining aninterior chamber 58 that optionally includes a spring. The bottom base comprises anaperture 60. The interior of the housing is adapted to receive areservoir chamber 62 having achamber ledge 62A circumferentially disposed around the interior of the upper end of thechamber 62. The reservoir chamber comprises abase 64 and a surroundingwall 66 extending upwards from the base defining achamber 62 with an open top 68. A filledreservoir body 70 is located in the reservoir chamber. - A single
hollow needle 72 is associated with thereservoir chamber 62. Theneedle 72 extends through thebase 64 of thechamber 62 and has a cannula with anupper end 74 communicating with the interior 75 of the reservoir chamber and alower end 78 projecting out of the chamber and down a predetermined distance. Theopen top 68 of the reservoir chamber is adapted to receive anactuator 80. In the illustrated embodiment, the actuator comprises aplunger 82 having anactivation flange 84 at one end and astopper 86 at the other end. In the initial position of the device as provided and as shown inFIGS. 2A and 2B , thebase 64 of thereservoir chamber 62 is held at a predetermined distance from theinterior surface 88 of thebase 56 of the housing by at least onereleasable latch 90 which retains the chamber in position by the interaction of thelatch 90 with alatch retainer 92. Thelatch 90 includes anotch 91. - In one preferred embodiment an
upper housing 96 encases theplunger 80. - It is clearly apparent that the distance the needle travels can be varied depending on the desired application and on the bubble position and the length of the needle. For example, the device can be adapted to have the needle travel a distance between about 0.5 mm to about 10 mm. Thus, the device of the invention can be adapted for intradermal, subcutaneous or intramuscular injections. The needle preferably travels from about 3 mm to 8 mm. The needle gauge is preferably 25 to 84 gauge although different gauge needles can be used.
- The operation of the device is illustrated sequentially in
FIGS. 2A to 2J .FIGS. 2A and 2B illustrate the device in the initial state as described above. Referring now toFIGS. 2C and 2D for use, thebase 56 of thehousing 52 is placed against the skin. When pressure is exerted on theactuator 80, thelatch 90 is released from theretainer 92. Theactuator 80 is connected to thereservoir chamber 62 via anotch 100 andtab 102 connector and the reservoir chamber will be forced down until thebase 64 of thereservoir chamber 62 hits theinterior surface 88 of thehousing base 56 and the chamber is stopped from any further downward movement. By adjusting the relative sizes and positions of the components, the length of the travel of the needle through the aperture into the skin can be tightly controlled. The distance that the needle extends is about 0.5 to 10 mm, preferably 0.5 to 5 mm, more preferably from about 3 mm to about 5 mm, even more preferably from about 1.5 to 3 mm. The outer layer of skin, the epidermis typically has a thickness of about 0.5 to 2 mm. and the inner layer, the dermis, has a thickness of about 1.5 to 3 mm. The dermis comprises two layers, the papillary layer and the reticular layer. The reticular layer contains many blood vessels and lymph vessels, making it a desirable area for delivery of active agents. Below the dermis is the subcutaneous layer and then muscle. In a preferred embodiment, the distance that the tip of the needle can extend beyond the lower outer surface of the housing is selected to be optimum for insertion in the dermis or subcutaneous layer. As thereservoir chamber 62, carrying theneedle 72 descends, the lower tip of theneedle 78 exits theaperture 60. The downward travel of thereservoir chamber 62 is limited when thebase 64 of the chamber contacts thebase 56 of the housing. In this way the travel of the needle through theaperture 60 is also limited so as to limit the depth of penetration of the needle into the skin. The components of the device have been configured so that the distance that the bottom of the chamber travels is translated into a predetermined travel for the needle through the aperture in the bottom of the housing to provide a certain skin penetration. - Referring now to
FIGS. 2E and 2F , as continued pressure is applied to theactuator 80, thetab 102 is released from thenotch 100 and theplunger 82 descends within the reservoir chamber forcing the filledreservoir 70 downwards until it contacts thebase 64 of thereservoir chamber 62. As theactuator 80 exerts pressure on thereservoir 70, thereservoir 70 contacts theupper end 74 of theneedle 72 and is punctured. The cannula of theneedle 72 is now in fluid communication with the contents of the reservoir. - Referring now to
FIGS. 2G and 2H , continued pressure on theactuator 80 compresses thereservoir 70 and forces all the contents to flow through theneedle 72 and into the patient. The downward travel of theactuator 80 is stopped when theplunger stopper 86 contacts thebase 64 of thereservoir chamber 62. - After use, the needle is preferably retracted back into the
housing 52 as illustrated inFIGS. 2I and 2J . The position of thereservoir chamber 62 carrying theneedle 72 is preferably biased to the pre-activation position by biasing means such as a spring, a vacuum bulb or a moldable bulb. Once pressure is released on theactuator 80, thebase 64 of the reservoir chamber moves up in the housing thus automatically retracting the used needle into the housing. This provides for safe disposal of the device. In a preferred embodiment, the needle is preferably locked in the retracted position.FIG. 2J shows a retracted reservoir chamber that is locked in position whentab 102 slides intoindent 104. - In the embodiment illustrated in
FIGS. 3A and 3B , anactuator 106 is continuous with anupper casing 108 that fits over ahousing 110. Thehousing 110 receives areservoir chamber 112 that has aneedle 114 transversely mounted through itsbase 116. A drug reservoir 118 is contained within thechamber 112. As shown inFIG. 3B , pressure on theactuator 106 causes thereservoir chamber 112 to descend until it abuts thebase 120 of thehousing 110. As thechamber 112 descends, it drives the tip 122 of theneedle 114 through anaperture 124 in thehousing 110. Further pressure causes the rear 126 of the needle to puncture the reservoir 118. Upon continued pressure, the contents of the reservoir are expelled through the needle. - In another embodiment, a flexible dome fits over the plunger rod and activation flange. It is also clearly apparent the manual activation flange can be exposed. The device also optionally includes a spring that is located around or below the reservoir chamber base such that when pressure on the activation flange is released the compressive energy of the spring causes the needle to be retracted back into the housing.
-
FIGS. 4A to 4C illustrate another embodiment of the device. Thedevice 130 includes ahousing 132 and anupper casing 134. Anactuator 136 is operably linked to areservoir chamber 138 disposed within thehousing 132. For use, a drug filledreservoir 140 is placed in thereservoir chamber 138. Aneedle 142 is mounted so as to transverse thebase 144 of thechamber 138. The device also includes aspring 146 that biases thereservoir chamber 138 upwards in thehousing 132. Upon pressure on theactuator 136, the spring compresses and the reservoir chamber travels downward carrying the needle and theneedle tip 148 exits thehousing 132. Upon further pressure, theactuator 136 compresses the drug filledreservoir 140 until the back 150 of the needle punctures the reservoir and the contents flow through the needle as shown inFIG. 4C . - In another aspect of the invention, a method for delivering an effective amount of a liquid active agent to an animal, preferably a human, is provided. The method comprises providing a drug delivery device according to the present invention, said device containing a reservoir filled with the desired drug; applying the bottom surface of the drug delivery device of the invention to the skin of an animal, applying pressure on the actuator to cause the needle to enter the skin, applying continued pressure to puncture the reservoir and deliver the contents of the reservoir through the cannula of the needle.
- The device of the present invention can be used to deliver a variety of active agents. The term “drug” is used loosely herein to refer to prophylactic as well as therapeutic agents. For example, vaccines may be delivered using the device. In addition, the term refers broadly to active agents, such as nucleic acids, small molecules, therapeutic proteins, hormones, analgesics, etc. in additional to traditional pharmacologic agents. Typical drugs include peptides, proteins or hormones such as insulin, calcitonin, calcitonin gene regulating protein, atrial natriuretic protein, colony stimulating factor, betaseton, erythropoietin (EPO), interferons such as α, β, or γ interferon, somatropin, somatotropin, somatostatin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone (LHRH), tissue plasminogen activator (TPA), growth hormone release hormone (GHRH), oxytocin, estradiol, growth hormones, leuprolide acetate, factor VIII, interleukins such as interleukin-2, and analogues thereof; analgesics such as fentanyl, sufentanil, butorphanol, buprenorphine, levorphanol, morphine, hydromorphone, hydrocodone, oxymorephone, methadone, lidocaine, bupivacaine, diclofenac, naproxen, pavefin, and analogues thereof; anti-migraine agents such as sumatriptan, ergot alkaloids, and analogues thereof, anti-coagulant agents such as hepafin, hirudin, and analogues thereof; anti-emetic agents such as scopolamine, ondansetron, domperidone, metoclopramide, and analogues thereof; cardiovascular agents, anti-hypertensive agents and vasodilator such as diltiazem, clonidine, nifedipine, verapamil, isosorbide-5-mononitrate, organic nitrates, agents used in treatment of heart disorders, and analogues thereof; sedatives such as benzodiazepines, phenothiozines, and analogues thereof; narcotic antagonists such as naltrexone, naloxone, and analogues thereof; chelating agents such as deferoxamine, and analogues thereof; anti-diuretic agents such as desmopressin, vasopressin, and analogues thereof; antineoplastics such as 5-fluorouracil, bleomycin, and analogues thereof; prostaglandins and analogues thereof; and chemotherapy agents such as vincristine, and analogues thereof. Stabilized preparations of drugs that can be stored at room temperature are particularly preferred for use in the device and method.
- The term “fluid” refers to any fluid containing an active agent or communication of agents that can pass through the cannula of the microneedle. This includes a liquid, a solution, a gel, a dispersion or a fine suspension.
- All citations are hereby incorporated by reference.
- The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/543,051 US20200360625A1 (en) | 2006-02-16 | 2019-08-16 | Drug delivery device |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002536845A CA2536845C (en) | 2006-02-16 | 2006-02-16 | Drug delivery device |
US11/355,000 US20070191780A1 (en) | 2006-02-16 | 2006-02-16 | Drug delivery device |
US13/229,538 US8597257B2 (en) | 2006-02-16 | 2011-09-09 | Drug delivery device |
US14/065,122 US20140207078A1 (en) | 2006-02-16 | 2013-10-28 | Drug delivery device |
US14/562,974 US20150273152A1 (en) | 2006-02-16 | 2014-12-08 | Drug delivery device |
US15/361,654 US20170203051A1 (en) | 2006-02-16 | 2016-11-28 | Drug delivery device |
US201816025179A | 2018-07-02 | 2018-07-02 | |
US201816227225A | 2018-12-20 | 2018-12-20 | |
US16/543,051 US20200360625A1 (en) | 2006-02-16 | 2019-08-16 | Drug delivery device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US201816227225A Continuation | 2006-02-16 | 2018-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200360625A1 true US20200360625A1 (en) | 2020-11-19 |
Family
ID=38371151
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/355,000 Abandoned US20070191780A1 (en) | 2006-02-16 | 2006-02-16 | Drug delivery device |
US13/229,538 Active - Reinstated 2026-04-21 US8597257B2 (en) | 2006-02-16 | 2011-09-09 | Drug delivery device |
US14/065,122 Abandoned US20140207078A1 (en) | 2006-02-16 | 2013-10-28 | Drug delivery device |
US14/562,974 Abandoned US20150273152A1 (en) | 2006-02-16 | 2014-12-08 | Drug delivery device |
US15/361,654 Abandoned US20170203051A1 (en) | 2006-02-16 | 2016-11-28 | Drug delivery device |
US16/543,051 Pending US20200360625A1 (en) | 2006-02-16 | 2019-08-16 | Drug delivery device |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/355,000 Abandoned US20070191780A1 (en) | 2006-02-16 | 2006-02-16 | Drug delivery device |
US13/229,538 Active - Reinstated 2026-04-21 US8597257B2 (en) | 2006-02-16 | 2011-09-09 | Drug delivery device |
US14/065,122 Abandoned US20140207078A1 (en) | 2006-02-16 | 2013-10-28 | Drug delivery device |
US14/562,974 Abandoned US20150273152A1 (en) | 2006-02-16 | 2014-12-08 | Drug delivery device |
US15/361,654 Abandoned US20170203051A1 (en) | 2006-02-16 | 2016-11-28 | Drug delivery device |
Country Status (13)
Country | Link |
---|---|
US (6) | US20070191780A1 (en) |
EP (1) | EP1983964B1 (en) |
JP (1) | JP5099370B2 (en) |
AU (1) | AU2007215343B2 (en) |
BR (1) | BRPI0707845B8 (en) |
CA (1) | CA2536845C (en) |
DK (1) | DK1983964T3 (en) |
EC (1) | ECSP088681A (en) |
ES (1) | ES2440247T3 (en) |
NZ (1) | NZ570532A (en) |
PL (1) | PL1983964T3 (en) |
WO (1) | WO2007093051A1 (en) |
ZA (1) | ZA200807006B (en) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486581B2 (en) * | 2002-09-11 | 2016-11-08 | Becton, Dickinson And Company | Injector device with force lock-out and injection rate limiting mechanisms |
MXPA06010784A (en) | 2004-03-26 | 2006-12-15 | Unomedical As | Injector device for infusion set. |
US8062250B2 (en) | 2004-08-10 | 2011-11-22 | Unomedical A/S | Cannula device |
US7985199B2 (en) | 2005-03-17 | 2011-07-26 | Unomedical A/S | Gateway system |
DK1762259T3 (en) | 2005-09-12 | 2011-01-03 | Unomedical As | Infusion set insertion device with a first and a second spring assembly |
PT1962925E (en) | 2005-12-23 | 2009-07-20 | Unomedical As | Device for administration |
US20070191780A1 (en) | 2006-02-16 | 2007-08-16 | Pankaj Modi | Drug delivery device |
CA2642415A1 (en) | 2006-02-28 | 2007-09-07 | Unomedical A/S | Inserter for infusion part and infusion part provided with needle protector |
MX2008015245A (en) | 2006-06-07 | 2008-12-15 | Unomedical As | Inserter for transcutaneous sensor. |
CA2653764A1 (en) | 2006-06-09 | 2007-12-13 | Unomedical A/S | Mounting pad |
RU2443436C2 (en) | 2006-08-02 | 2012-02-27 | Уномедикал А/С | Cannula and delivery device |
EP1917990A1 (en) | 2006-10-31 | 2008-05-07 | Unomedical A/S | Infusion set |
WO2008097217A1 (en) * | 2007-02-07 | 2008-08-14 | Becton, Dickinson And Company | Safety shield system for a single use flexible-type compression syringe, and injection device |
US9186480B2 (en) | 2007-06-20 | 2015-11-17 | Unomedical A/S | Apparatus for making a catheter |
NZ582194A (en) | 2007-07-03 | 2011-08-26 | Unomedical As | Inserter for injecting medication having bistable equilibrium states |
DK2173410T3 (en) | 2007-07-10 | 2011-06-06 | Unomedical As | Two-spring inserts |
NZ587111A (en) | 2008-02-13 | 2012-03-30 | Unomedical As | Infusion part including seal between cannula and fluid inlet or outlet |
MX2010009087A (en) | 2008-02-20 | 2011-05-03 | Unomedical As | Insertion device with horizontally moving part. |
JP5653350B2 (en) * | 2008-06-19 | 2015-01-14 | ベティ,ラヴィンダー | Device that detects epidural space while preventing dural puncture by resistance difference technique |
EP2293831A1 (en) * | 2008-07-07 | 2011-03-16 | Unomedical A/S | Inserter for transcutaneous device |
NL1036024C (en) * | 2008-10-07 | 2010-04-08 | Hubertus Eduard Hilbrink | DEVICE AND METHOD FOR DELIVERING A LIQUID FROM A PACKAGING. |
MX2011005735A (en) | 2008-12-22 | 2011-06-21 | Unomedical As | Medical device comprising adhesive pad. |
JP5517029B2 (en) * | 2009-03-25 | 2014-06-11 | ニプロ株式会社 | Chemical self-injection device |
KR101030752B1 (en) * | 2009-04-09 | 2011-04-26 | 한국생명공학연구원 | A Micro Needle Unit Having Controlling Function of Fluid Delivery |
CA2766475A1 (en) | 2009-07-30 | 2011-02-03 | Unomedical A/S | Inserter device with horizontal moving part |
RU2012108579A (en) | 2009-08-07 | 2013-09-20 | Уномедикал А/С | DELIVERY DEVICE WITH SENSOR AND ONE OR MULTIPLE CANULES |
US20110046559A1 (en) | 2009-08-21 | 2011-02-24 | Becton Dickinson France S.A.S. | Syringe Assembly Having a Flexible or Slidable Flange |
IN2012DN02414A (en) * | 2009-09-15 | 2015-08-21 | Becton Dickinson Co | |
US20110172638A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Drug delivery device including multi-functional cover |
WO2011089206A2 (en) | 2010-01-22 | 2011-07-28 | Sanofi-Aventis Deutschland Gmbh | Coded collapsible drug reservoir |
CN105536109B (en) * | 2010-02-01 | 2021-04-09 | 贝克顿·迪金森公司 | Low dose pre-filled drug delivery device and method |
DE102010001506A1 (en) * | 2010-02-02 | 2011-08-04 | Vosseler, Michael, 78073 | Dermal access device |
JP2013523202A (en) | 2010-03-25 | 2013-06-17 | ニュー インジェクション システムズ リミテッド | Syringe |
DE102010013543B3 (en) * | 2010-03-26 | 2011-06-30 | Ing. Erich Pfeiffer GmbH, 78315 | Discharge device for liquids |
CA2792138A1 (en) | 2010-03-30 | 2011-10-06 | Unomedical A/S | Medical device |
JP5809242B2 (en) * | 2010-04-21 | 2015-11-10 | アッヴィ バイオテクノロジー リミテッド | Wearable automatic infusion device for controlled delivery of therapeutic agents |
US9808583B2 (en) * | 2010-08-23 | 2017-11-07 | Nanbu Plastics Co., Ltd. | Percutaneous medication device and needle formation used for the device |
EP2433663A1 (en) | 2010-09-27 | 2012-03-28 | Unomedical A/S | Insertion system |
EP2436412A1 (en) | 2010-10-04 | 2012-04-04 | Unomedical A/S | A sprinkler cannula |
US8668675B2 (en) | 2010-11-03 | 2014-03-11 | Flugen, Inc. | Wearable drug delivery device having spring drive and sliding actuation mechanism |
US9180253B2 (en) | 2010-11-03 | 2015-11-10 | Sanofi-Aventis Deutschland Gmbh | Medicated module for administering fixed dose |
CN103189083B (en) * | 2010-11-03 | 2015-06-10 | 赛诺菲-安万特德国有限公司 | Medicated module with deformable membrane |
US20120253314A1 (en) * | 2011-03-30 | 2012-10-04 | Ziv Harish | Palm-controlled injectors |
JP5897113B2 (en) * | 2011-05-18 | 2016-03-30 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | Injection device |
CN103857427B (en) * | 2011-07-25 | 2018-01-30 | 普雷斯弗雷克斯股份公司 | Fluid distributor |
CA2845888A1 (en) | 2011-09-13 | 2013-03-21 | Sanofi-Aventis Deutschland Gmbh | Safety device and injection device |
EP2572743A1 (en) * | 2011-09-23 | 2013-03-27 | Sanofi-Aventis Deutschland GmbH | Needle safety device |
US11197689B2 (en) | 2011-10-05 | 2021-12-14 | Unomedical A/S | Inserter for simultaneous insertion of multiple transcutaneous parts |
EP2583715A1 (en) | 2011-10-19 | 2013-04-24 | Unomedical A/S | Infusion tube system and method for manufacture |
US9440051B2 (en) | 2011-10-27 | 2016-09-13 | Unomedical A/S | Inserter for a multiplicity of subcutaneous parts |
GB201206766D0 (en) * | 2012-04-17 | 2012-05-30 | Univ Antwerpen | Prefillable intradermal delivery device |
GB201210082D0 (en) * | 2012-06-07 | 2012-07-25 | Consort Medical Plc | Improved syringe |
WO2014080020A1 (en) | 2012-11-23 | 2014-05-30 | New Injection Systems Ltd | Auto-injector assembly |
US10398856B2 (en) | 2013-11-14 | 2019-09-03 | Hahn-Schickard-Gesellschaft Fuer Angewandte Forschung E.V. | Access device |
DK3104905T3 (en) * | 2014-02-12 | 2021-06-28 | Sanofi Aventis Deutschland | MEDICINE ADMINISTRATION DEVICE WITH COMPRESSIBLE RESERVOIR FOR LIQUID MEDICINE |
NL2012570B1 (en) * | 2014-04-04 | 2016-03-08 | Sparkle Innovations B V | Device and method for applying a liquid drop by drop. |
AU2015253253B2 (en) * | 2014-04-30 | 2019-09-12 | Sorrento Therapeutics, Inc. | Transdermal drug delivery apparatus and methods |
US10111807B2 (en) * | 2014-04-30 | 2018-10-30 | Sorrento Therapeutics, Inc. | Cartridge portion of transdermal drug delivery apparatus and methods |
US10543317B2 (en) * | 2014-06-04 | 2020-01-28 | Merck Sharp & Dohme Corp. | Prefilled disposable injection device |
EP2965779A1 (en) * | 2014-07-07 | 2016-01-13 | MT Derm GmbH | Application module for a handheld device for repeated application of an application element to a human or an animal skin and hand-held device |
US20160175544A1 (en) * | 2014-12-18 | 2016-06-23 | Marc Andrew Koska | Single use injection system |
US20160228634A1 (en) * | 2015-02-06 | 2016-08-11 | Regeneron Pharmaceuticals, Inc. | Aseptic drug delivery system and methods |
US11123499B2 (en) * | 2016-01-19 | 2021-09-21 | Merck Sharp & Dohme Corp. | Prefilled disposable injection device |
ITUB20160615A1 (en) * | 2016-02-10 | 2017-08-10 | Orofino Pharmaceuticals Group Srl | Cartridge and syringe for injection of a pharmaceutical solution and method for cartridge production |
EP3436111B1 (en) | 2016-04-01 | 2024-02-28 | Idevax Bv | Injection device |
GB2549494A (en) * | 2016-04-19 | 2017-10-25 | Stephen Douglas Philip | Apparatus for administering liquid to an individual's skin |
JP7246318B2 (en) * | 2016-12-15 | 2023-03-27 | ピーケイエイ ソフトタッチ コーポレイション | Intradermal drug delivery device with locked post-dispensing configuration |
US11752068B2 (en) * | 2017-10-19 | 2023-09-12 | Sanofi | Medicament container and drug delivery device |
EP3930794A1 (en) * | 2017-11-21 | 2022-01-05 | Sanofi | A container for at least a first injectable medicament and injection device |
CN108553112B (en) * | 2018-03-16 | 2021-07-13 | 北京华诺信得科技有限公司 | Vaccine activity detection extractor |
US11771842B2 (en) | 2019-05-09 | 2023-10-03 | Medicines360 | Syringes, syringe containers, kits and methods of use |
CN112043954A (en) * | 2019-06-05 | 2020-12-08 | 美帕信息科技(上海)有限公司 | Newly born muscle leading-in instrument |
EP4340911A1 (en) * | 2021-05-21 | 2024-03-27 | SHL Medical AG | Medicament delivery device |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3255752A (en) * | 1965-01-28 | 1966-06-14 | Dick Peter | Hypodermic syringe |
US5413564A (en) * | 1994-03-02 | 1995-05-09 | Silver; Jules | Predetermined dosage hypodermic syringe system |
US5827233A (en) * | 1995-12-26 | 1998-10-27 | Nissno Corporation | Prefilled syringe |
US6620134B1 (en) * | 1998-11-23 | 2003-09-16 | Medrad, Inc. | Syringes and injector systems with collapsible cartridges |
US20080208125A1 (en) * | 2004-06-23 | 2008-08-28 | Owen Mumford Limited | Automatic Injection Devices |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2371086A (en) * | 1940-11-14 | 1945-03-06 | Watson | Hypodermic injector |
US2667872A (en) * | 1952-03-19 | 1954-02-02 | Arthur E Smith | Syringe unit |
US3527215A (en) * | 1967-02-20 | 1970-09-08 | American Hospital Supply Corp | Syringe construction having internal bladder |
US4258713A (en) * | 1979-07-23 | 1981-03-31 | Wardlaw Stephen C | Automatic disposable hypodermic syringe |
CA1283827C (en) * | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
US4883473A (en) * | 1987-04-29 | 1989-11-28 | Path | Single use injection device |
US4955871A (en) * | 1987-04-29 | 1990-09-11 | Path | Single-use disposable syringe |
ATA228987A (en) * | 1987-09-09 | 1993-07-15 | Pickhard Ewald | INJECTION DEVICE WITH A DEFORMABLE Vial |
US4925055A (en) * | 1988-03-04 | 1990-05-15 | Edward S. Robbins, III | Container with unitary bladder and associated dispenser cap |
KR910004532Y1 (en) * | 1989-06-15 | 1991-06-29 | 방영철 | Syringe |
US5527288A (en) * | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
CA2126320C (en) * | 1992-01-24 | 2006-09-05 | Kenneth W. Rake | Platen pump |
CA2132277C (en) * | 1993-10-22 | 2005-05-10 | Giorgio Cirelli | Injection device |
US5997501A (en) * | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
EP0695554B1 (en) * | 1994-07-27 | 1999-01-07 | Meridian Medical Technologies, Inc. | Automatic injector |
CA2159052C (en) * | 1994-10-28 | 2007-03-06 | Rainer Alex | Injection device |
US5964736A (en) * | 1995-09-22 | 1999-10-12 | Lane; Donovan R. | Livestock biological and vaccine handling system |
US5658259A (en) * | 1995-10-19 | 1997-08-19 | Meridian Medical Technologies, Inc. | Dental cartridge assembly auto-injector with protective needle cover |
JPH10174717A (en) * | 1996-12-18 | 1998-06-30 | Daikyo Seiko:Kk | Injector assembly |
US6607509B2 (en) * | 1997-12-31 | 2003-08-19 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
AUPP313398A0 (en) * | 1998-04-22 | 1998-05-14 | Boston Research And Development Company | Disposable fluid or particulate applicator |
GB2351272B (en) * | 1999-06-23 | 2001-05-02 | Eu Pharma Ltd | Oral medicine dispenser |
US6102896A (en) * | 1999-09-08 | 2000-08-15 | Cambridge Biostability Limited | Disposable injector device |
US6494865B1 (en) * | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US20020095134A1 (en) * | 1999-10-14 | 2002-07-18 | Pettis Ronald J. | Method for altering drug pharmacokinetics based on medical delivery platform |
US6569143B2 (en) * | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
US20020193740A1 (en) * | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
US6585698B1 (en) * | 1999-11-01 | 2003-07-01 | Becton, Dickinson & Company | Electronic medical delivery pen having a multifunction actuator |
US6387078B1 (en) * | 2000-12-21 | 2002-05-14 | Gillespie, Iii Richard D. | Automatic mixing and injecting apparatus |
AT411222B (en) * | 2001-10-31 | 2003-11-25 | Juette Werner Dr | DISPOSABLE INJECTION DEVICE |
US6808507B2 (en) * | 2002-05-10 | 2004-10-26 | Cambridge Biostability Ltd. | Safety injectors |
US6979316B1 (en) * | 2002-05-23 | 2005-12-27 | Seedlings Life Science Ventures Llc | Apparatus and method for rapid auto-injection of medication |
US6896666B2 (en) * | 2002-11-08 | 2005-05-24 | Kochamba Family Trust | Cutaneous injection delivery under suction |
EP1452196A1 (en) * | 2003-02-25 | 2004-09-01 | Jean-Denis Rochat | Device and method of making the package of medicament |
CA2536854C (en) | 2005-02-16 | 2014-12-02 | Zero Zone, Inc. | Refrigerant tracking/leak detection system and method |
US7645264B2 (en) * | 2005-04-11 | 2010-01-12 | Becton, Dickinson And Company | Injection device with secondary reservoir |
FR2884721A1 (en) * | 2005-04-20 | 2006-10-27 | Becton Dickinson France Soc Pa | Assistance device for device of injection of a product, comprises hollow body for receiving the product, hollow injection needle for penetrating into injection site, piston placed in the body, hollow sleeve with bearing surface |
US20070191780A1 (en) | 2006-02-16 | 2007-08-16 | Pankaj Modi | Drug delivery device |
-
2006
- 2006-02-16 US US11/355,000 patent/US20070191780A1/en not_active Abandoned
- 2006-02-16 CA CA002536845A patent/CA2536845C/en active Active
-
2007
- 2007-02-15 BR BRPI0707845A patent/BRPI0707845B8/en active IP Right Grant
- 2007-02-15 PL PL07701776T patent/PL1983964T3/en unknown
- 2007-02-15 EP EP07701776.2A patent/EP1983964B1/en active Active
- 2007-02-15 JP JP2008554571A patent/JP5099370B2/en not_active Expired - Fee Related
- 2007-02-15 AU AU2007215343A patent/AU2007215343B2/en active Active
- 2007-02-15 ES ES07701776.2T patent/ES2440247T3/en active Active
- 2007-02-15 DK DK07701776.2T patent/DK1983964T3/en active
- 2007-02-15 WO PCT/CA2007/000225 patent/WO2007093051A1/en active Application Filing
- 2007-02-15 NZ NZ570532A patent/NZ570532A/en active IP Right Revival
-
2008
- 2008-08-14 ZA ZA200807006A patent/ZA200807006B/en unknown
- 2008-08-15 EC EC2008008681A patent/ECSP088681A/en unknown
-
2011
- 2011-09-09 US US13/229,538 patent/US8597257B2/en active Active - Reinstated
-
2013
- 2013-10-28 US US14/065,122 patent/US20140207078A1/en not_active Abandoned
-
2014
- 2014-12-08 US US14/562,974 patent/US20150273152A1/en not_active Abandoned
-
2016
- 2016-11-28 US US15/361,654 patent/US20170203051A1/en not_active Abandoned
-
2019
- 2019-08-16 US US16/543,051 patent/US20200360625A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3255752A (en) * | 1965-01-28 | 1966-06-14 | Dick Peter | Hypodermic syringe |
US5413564A (en) * | 1994-03-02 | 1995-05-09 | Silver; Jules | Predetermined dosage hypodermic syringe system |
US5827233A (en) * | 1995-12-26 | 1998-10-27 | Nissno Corporation | Prefilled syringe |
US6620134B1 (en) * | 1998-11-23 | 2003-09-16 | Medrad, Inc. | Syringes and injector systems with collapsible cartridges |
US20080208125A1 (en) * | 2004-06-23 | 2008-08-28 | Owen Mumford Limited | Automatic Injection Devices |
Also Published As
Publication number | Publication date |
---|---|
US8597257B2 (en) | 2013-12-03 |
DK1983964T3 (en) | 2014-01-20 |
ES2440247T3 (en) | 2014-01-28 |
CA2536845A1 (en) | 2007-08-16 |
BRPI0707845B1 (en) | 2020-08-25 |
EP1983964A4 (en) | 2009-04-08 |
ZA200807006B (en) | 2009-10-28 |
BRPI0707845B8 (en) | 2021-06-22 |
ECSP088681A (en) | 2008-10-31 |
JP5099370B2 (en) | 2012-12-19 |
US20070191780A1 (en) | 2007-08-16 |
BRPI0707845A8 (en) | 2018-10-30 |
US20150273152A1 (en) | 2015-10-01 |
NZ570532A (en) | 2011-09-30 |
BRPI0707845A2 (en) | 2011-05-10 |
WO2007093051A1 (en) | 2007-08-23 |
AU2007215343B2 (en) | 2012-08-23 |
EP1983964A1 (en) | 2008-10-29 |
JP2009526575A (en) | 2009-07-23 |
US20170203051A1 (en) | 2017-07-20 |
PL1983964T3 (en) | 2014-03-31 |
AU2007215343A1 (en) | 2007-08-23 |
EP1983964B1 (en) | 2013-10-09 |
US20140207078A1 (en) | 2014-07-24 |
US20110319834A1 (en) | 2011-12-29 |
CA2536845C (en) | 2009-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200360625A1 (en) | Drug delivery device | |
EP1379299B1 (en) | Prefillable intradermal injector | |
US20030109827A1 (en) | Drug delivery system and method | |
US6569123B2 (en) | Prefillable intradermal injector | |
US9682198B2 (en) | Intradermal injection device | |
US5858001A (en) | Cartridge-based drug delivery device | |
US6099504A (en) | Pre-filled injection delivery device | |
AU2001297971A1 (en) | Prefillable intradermal injector | |
ZA200307922B (en) | Prefillable intradermal injector. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: PKA SOFTTOUCH CORP., ONTARIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MODI, PANKAJ, DR.;REEL/FRAME:063496/0404 Effective date: 20060419 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |